Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 27, 2015 11:44 PM ET

Health Care Technology

Company Overview of NextGxDx Inc.

Company Overview

NextGxDx Inc. operates as a healthcare IT company that focuses on enhancing the genetic test ordering process for the medical community. Its portfolio includes GeneSource, a tool available for physicians and other healthcare professionals to search for, compare, and order genetic tests from various laboratories; and GeneConnect, a utilization management solution that leverages the GeneSource database and provides hospitals and sendout laboratories with the tools to lower costs and address workflow inefficiencies associated with the genetic test ordering process. The company was founded in 2010 and is based in Franklin, Tennessee.

810 Crescent Centre Drive

Suite 280

Franklin, TN 37067

United States

Founded in 2010



Key Executives for NextGxDx Inc.

Founder, Chief Executive Officer and Director
Chief Financial Officer
Chief Technology Officer
Senior Vice President of Business Development
Vice President of Bioinformatics
Compensation as of Fiscal Year 2015.

NextGxDx Inc. Key Developments

Novation Awards Group Purchasing Contract to NextGxDx, Inc

Novation announced that it has awarded a group purchasing contract to NextGxDx Inc. Under the agreement, Children's Hospital Association (CHA) members who participate with Novation will have access to NextGxDx's GeneConnect genetic testing utilization management solution, as well as the resources available through NextGxDx's collaboration with the Seattle Children's Hospital PLUGS (Pediatric Laboratory Utilization Guidance Services) program. In addition to GeneConnect, the Novation agreement includes NextGxDx's collaboration with the Seattle Children's Hospital's PLUGS program, which helps clinical laboratories and hospitals improve the value of laboratory tests by reducing costs and errors associated with unnecessary testing. PLUGS members are provided a customized strategic plan on how to develop and sustain an internal utilization management program, as well as access to practical tools, expert advice and to the valuable PLUGS peer network.

Seattle Children's Hospital Collaborates with NextGxDx, Inc. to Develop a Joint Genetic Test Utilization Management

Seattle Children's Hospital announced that it will collaborate with NextGxDx Inc. to develop a joint genetic test utilization management (UM) solution for children's hospitals and pediatric practices. The collaboration will combine the hospital's PLUGS UM program and its team of genetic testing experts with NextGxDx's GeneConnect platform, a technology solution designed to bring highly specialized data and tools to help curb rising genetic testing send-out costs. The collaboration was announced at the first annual PLUGS Summit Utilization Management Conference. PLUGS, which stands for Pediatric Laboratory Utilization Guidance Services, helps clinical laboratories and practitioners decrease costs and errors associated with unnecessary laboratory testing by providing practical resources, expert advice and a valuable peer network for members to develop sustainable utilization management programs.

NextGxDx Inc. Announces Appointments to its Board

NextGxDx Inc. announced the successful closing of the company's Series B round of financing, which was led by Voyent Partners and joined by the Nashville Capital Network. With the new investment, the company has expanded its board of directors to include new members Patrick J. Balthrop Sr.; Phil Hertik; Jim Kever; George Lazenby; and G. Walter Loewenbaum II. Balthrop has served as the president and chief executive officer of Luminex Corp. Hertik is the former founder, chairman and CEO of Windsor Health Group. Kever has been a principal in Voyent Partners, since 2001. He is also a director of Luminex Corp. and Tyson Foods Inc. Lazenby most recently served as chief executive officer of Emdeon and was a member of its board of directors since September 2008. Mr. Lazenby is currently a senior advisor for Emdeon's majority investor, Blackstone Capital Partners. Loewenbaum has been the chairman of Luminex Corp. since 2002 and 3D Systems Corp. The new members join current board members Harris and James Lackey, chairman and CEO of Complete Holdings Group. Kever will serve as the new Chairman.

Similar Private Companies By Industry

Company Name Region
OPUS-ISM, LLC United States
Medical Office Software, Inc. United States
Azzur IT United States
ExpertAngle United States
MEDITECH Solutions Group United States

Recent Private Companies Transactions

Private Placement
September 24, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NextGxDx Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at